Molecular Partners Announces Publication In Nature Biotechnology Detailing Design And Mechanism Of Ensovibep DARPin Antiviral For SARS-CoV-2
Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced the publication of key